Brief: Reata Pharmaceuticals Plans NDA Submission For Omaveloxolone In Q1 Of 2022 Following Completion Of Pre-NDA Meeting With FDA
30/09/2021 12:01
Sept 30 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS PLANS NDA SUBMISSION FOR
OMAVELOXOLONE IN
FIRST QUARTER OF 2022 FOLLOWING COMPLETION OF PRE-NDA MEETING
WITH FDA
* REATA PHARMACEUTICALS INC - NOT PLANNING TO CONDUCT A
SECOND
PRE-APPROVAL CLINICAL STUDY PRIOR TO SUBMISSION
Source text for Eikon: ID:nBw7KdKj6a
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer